Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0057)
Name
Thioguanine
Synonyms
thioguanine; 6-Thioguanine; 154-42-7; Tioguanine; 2-Amino-6-mercaptopurine; 6-Mercaptoguanine; Tabloid; 2-Amino-6-purinethiol; Tioguanin; Lanvis; 2-Amino 6MP; 2-Aminopurin-6-thiol; 2-Aminopurine-6-thiol; 2-Aminopurine-6(1H)-thione; 2-Amino-9H-purine-6-thiol; Wellcome U3B; 6-Mercapto-2-aminopurine; 6-TG; 2-Amino-6-merkaptopurin; Tioguaninum; Guanine, thio-; 2-amino-1H-purine-6(7H)-thione; Tioguanina; 6H-Purine-6-thione, 2-amino-1,7-dihydro-; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-amino-3,7-dihydropurine-6-thione; Thioguanine Anhydrous; NSC-752; BW 5071; Purine-6-thiol, 2-amino-; Purine-6(1H)-thione, 2-amino-; 2-Amino-1,9-Dihydro-6h-Purine-6-Thione; TG; C5H5N5S; Thioguanine, anhydrous; THG; NSC 752; 2-Amino-1,7-dihydro-6H-purin-6-thion; X 27; 2-amino-6,7-dihydro-3H-purine-6-thione; 6-TG/Thioguanine; Tioguanine (INN); Tioguanine [INN]; 2-amino-3,7-dihydro-6H-purine-6-thione; 2-amino-1,9-dihydropurine-6-thione; CHEMBL727; WIX31ZPX66; CHEBI:9555; NSC752; DTXSID6023652; Thioguanine2-Amino-6-purinethiol; 2-Thioguanine; 2-amino-1H-purine-6(9H)-thione; NSC-76504; NCGC00094792-01; 2-Amino-6-MP; Tioguanine hemihydrate; Tioguaninum [INN-Latin]; DTXCID803652; 2-Aminopurin-6-thiol [Czech]; Guanine, thio- (VAN); 2-Amino-6-merkaptopurin [Czech]; 6-Tioguanine; Tioguanina [INN-Spanish]; CAS-154-42-7; DX4; SMR000857244; Lanvis (TN); CCRIS 8997; HSDB 2504; SR-05000002077; EINECS 205-827-2; Thioguanine [USAN:USP]; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; UNII-WIX31ZPX66; Thioquanine; AI3-26078; 6-thioguano-sine; MFCD00233553; 1330266-29-9; Spectrum_000235; THIOGUANINE [MI]; Spectrum2_000695; Spectrum3_000577; Spectrum4_000926; Spectrum5_001455; purine antimetabolite: antimetabolite: inhibits nucleic acid replication; THIOGUANINE [HSDB]; 2-Amino-6-mercapto-purin; 6-Thioguanine, >=98%; SCHEMBL3701; SCHEMBL5898; NCIOpen2_004153; TIOGUANINE [WHO-DD]; BSPBio_001994; KBioGR_001452; KBioGR_002476; KBioSS_000715; KBioSS_002483; MLS001333131; MLS001333132; MLS006010896; DivK1c_000428; SPECTRUM1500573; SPBio_000849; 154-42-7; 6-Thioguanine; 2-amino-6-mercapto-9H-purine; GTPL6845; Thioguanine (TN) (GlaxoSmith); HMS501F10; KBio1_000428; KBio2_000715; KBio2_002476; KBio2_003283; KBio2_005044; KBio2_005851; KBio2_007612; KBio3_001494; KBio3_002954; cMAP_000061; NINDS_000428; BCPE000001; HMS1921E09; HMS2092M11; HMS2235F05; HMS3865G13; Pharmakon1600-01500573; BCP27718; Tox21_111035; Tox21_113184; Tox21_202401; Tox21_300275; BDBM50200099; CCG-39890; HB1379; NSC757348; s1774; AKOS003389499; AKOS015901298; Tox21_111035_1; 2-Amino-1,7-dihydro-purine-6-thione; 2-Amino-1,9-dihydro-purine-6-thione; AC-8421; BCP9000197; CCG-213953; CCG-266338; CS-1497; DB00352; NSC-757348; PS-5007; WLN: T56 BNM FYM INJ FUS HZ; IDI1_000428; SMP2_000326; NCGC00094792-02; NCGC00094792-03; NCGC00094792-05; NCGC00094792-06; NCGC00094792-17; NCGC00188976-01; NCGC00188976-02; NCGC00254082-01; NCGC00259950-01; NCGC00263442-01; NCGC00263442-02; NCGC00263442-05; 157646-93-0; AC-23020; BT166463; HY-13765; NCI60_041643; SMR004701808; SBI-0051533.P003; FT-0611217; T0212; 2-Amino-1,7-dihydro-6H-purine-6-thione #; C07648; D08603; EN300-119530; T71841; AB00174074_06; AB00918694_06; AB01273926-01; AB01273926-02; AB01273926_03; A809532; Q385347; SR-05000002077-1; SR-05000002077-5; W-108030; W-205813; Z2299468139; 6-Thioguanine;6-TG;2-Amino-6-mercaptopurine;2-Amino-6-purinethiol; Thioguanine, United States Pharmacopeia (USP) Reference Standard; Thioguanine;6-TG; 2-Amino-6-mercaptopurine; 2-Amino-6-purinethiol; 6-Thioguanine, Hybri-Max(TM), 50 x, gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 611-67-6

    Click to Show/Hide
Structure
Formula
C5H5N5S
IUPAC Name
2-amino-3,7-dihydropurine-6-thione
Canonical SMILES
C1=NC2=C(N1)C(=S)N=C(N2)N
InChI
InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
InChIKey
WYWHKKSPHMUBEB-UHFFFAOYSA-N
PubChem CID
2723601
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model MGC-803 cells Gastric mucinous adenocarcinoma Homo sapiens CVCL_5334
AGS cells Gastric adenocarcinoma Homo sapiens CVCL_0139
In Vivo Model
Female BALB/c nude mice (6-7 weeks, 17-18 g) were purchased from Hunan Slack Scene of Laboratory Animal Co., Ltd. and used to establish the xenograft mouse model with 5 x 106 exponentially growing MGC-803 cells inoculated subcutaneously into the right forelimb for each mouse. Once the volume of tumors reached 100 mm3, the mice were divided into 3 groups: solvent control; 6-TG (10 mg/kg/day); 6-TG (10 mg/kg/day) + Fer-1(50 mg/kg/day).

    Click to Show/Hide
Response regulation 6-Thioguanine was identified as a potential ferroptosis inducer in gastric cancer cells for the first time. It could inactivate system xc, block the generation of GSH, down-regulate the expression of GPX4, increase the level of Lipid ROS, and finally trigger the Fe-2+-mediated ferroptosis in MGC-803 and AGS cell lines.
References
Ref 1 From DNMT1 degrader to ferroptosis promoter: Drug repositioning of 6-Thioguanine as a ferroptosis inducer in gastric cancer. Biochem Biophys Res Commun. 2022 May 7;603:75-81. doi: 10.1016/j.bbrc.2022.03.026. Epub 2022 Mar 6.